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Abstract: Doxorubicin is a strong inducer of immunogenic cell death (ICD), but it is ineffective
in P-glycoprotein (Pgp)-expressing cells. Indeed, Pgp effluxes doxorubicin and impairs the
immunesensitizing functions of calreticulin (CRT), an “eat-me” signal mediating ICD. It is unknown
if classical Pgp inhibitors, designed to reverse chemoresistance, may restore ICD. We addressed
this question by using Pgp-expressing cancer cells, treated with Tariquidar, a clinically approved
Pgp inhibitor, and R-3 compound, a N,N-bis(alkanol)amine aryl ester derivative with the same
potency of Tariquidar as Pgp inhibitor. In Pgp-expressing/doxorubicin-resistant cells, Tariquidar
and R-3 increased doxorubicin accumulation and toxicity, reduced Pgp activity, and increased CRT
translocation and ATP and HMGB1 release. Unexpectedly, only R-3 promoted phagocytosis by
dendritic cells and activation of antitumor CD8+T-lymphocytes. Although Tariquidar did not alter the
amount of Pgp present on cell surface, R-3 promoted Pgp internalization and ubiquitination, disrupting
its interaction with CRT. Pgp knock-out restores doxorubicin-induced ICD in MDA-MB-231/DX
cells that recapitulated the phenotype of R-3-treated cells. Our work demonstrates that plasma
membrane-associated Pgp prevents a complete ICD notwithstanding the release of ATP and HMGB1,
and the exposure of CRT. Pharmacological compounds reducing Pgp activity and amount may act as
promising chemo- and immunesensitizing agents.
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1. Introduction
The ability of cancer cells to escape from the immune system and the cytotoxicity of chemotherapy
are two reasons for bad prognosis in oncological patients. To induce an immune-mediated killing,
dying cancer cells must produce several damage-associated molecular pattern (DAMP) messengers
that cause cancer cells to be recognized by immune cells and trigger the so-called immunogenic cell
death (ICD) [1,2]. Both surface and soluble molecules are required to induce ICD in response to
chemotherapeutic drugs such as anthracyclines, oxaliplatin, taxanes, alkylating agents, and proteasome
inhibitors [2–4]. The exposure of calreticulin (CRT) on cell surface and the release of ATP and High
Mobility Group Box 1 (HMGB1) protein are potent signals that engage dendritic cells (DCs), stimulate
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phagocytosis and antigen processing, and expand cytotoxic CD8+T-lymphocytes (CTLs) with antitumor
activity [2,5]. CRT, a chaperon protein usually residing within endoplasmic reticulum (ER), translocates
to the plasmamembrane, bound to the ERp57 protein. By engaging the LDL receptor-related protein
1/CD91 receptor on DCs, the dimer CRT/ERp57 initiates the phagocytosis of dying cancer cells [6,7].
Soluble ATP binds the purinergic receptor P2X7 on DCs; this step is followed by the activation of
NOD-like receptor family, pyrin domain containing-3 protein (NLRP3)-dependent caspase-1 complex.
This complex, also known as the inflammasome, increases the production of IL-1β, facilitating the
recruitment of CTLs producing IFN-γ [8]. ATP is necessary to induce ICD, as demonstrated by the
abrogation of chemotherapy-induced ICD in the presence of the activated ecto-ATPases CD39 [9] and
CD73 [10]. HMGB1, together with the surface heat shock protein 90 (HSP90), acts as a ligand of Toll-like
receptor-4 (TLR4): this interaction stimulates the antigens processing by DCs, which is the premise
to expand CTLs directed against cancer cells [11]. Overall, the cooperation between CRT-, ATP-,
and HMGB1-dependent signals is crucial to promote DC homing and recruitment, antigens processing,
and antitumor CTLs engagement [12].
Several factors may limit the efficacy of ICD, such as the tumor mutational burden;
the tumor microenvironment containing specific populations, e.g., cancer-associated fibroblasts
(CAFs), M2-tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs),
and T-regulatory cells (Tregs), inhibiting the expansion of CTLs; and the chemotherapy protocols based
on few administrations of the maximum tolerated dose instead of metronomic protocols [13].
In addition, another factor impairing ICD is the intrinsic or acquired resistance to chemotherapy.
Doxorubicin, a topoisomerase IIα inhibitor, is an excellent inducer of ICD [14]. However,
we demonstrated that cells resistant to necro-apoptotic death induced by doxorubicin are also resistant
to ICD [15–17]. One of the main mechanisms involved in the resistance to doxorubicin is the presence
on the cell surface of efflux proteins belonging to the ATP Binding Cassette (ABC) transporters, such as
ATP Binding Cassette transporter B1 or P-glycoprotein (ABCB1/Pgp), ATP Binding Cassette transporter
C1 or multidrug resistance-related protein 1 (ABCC1/MRP1), and ATP Binding Cassette transporter
G2 or breast cancer resistance-related protein (ABCG2/BCRP) [18]. By reducing the intracellular
concentration of doxorubicin, these proteins limit all of doxorubicin’s death mechanisms, including
ICD [15]. Furthermore, we demonstrated that Pgp, which is synthesized within the ER, is transported
to the plasma membrane, following the same mechanism of CRT: here, Pgp co-localizes with CRT
and prevents cell phagocytosis by DCs [19]. In the last decades, three generations of Pgp/interacting
compounds, including substrates, inhibitors, or modulators [20], have been developed with the aim of
reversing chemoresistance in Pgp-expressing tumors [21]. Most of them failed because of heavy side
effects, unexpected drug–drug interactions with chemotherapeutic agents, or poor pharmacokinetic
profiles [20]. Tariquidar is one of the latest compounds approved for clinical trials: it is tolerable and
does not impair the pharmacokinetics of chemotherapeutic drugs; unfortunately, the real efficacy in
terms of anticancer effects is doubtful and it has not been approved for therapy [22]. Until now, there
are no studies investigating if Pgp inhibitors can also rescue the ICD induced by chemotherapeutic
Pgp substrates like doxorubicin.
In the present work, we investigated how Pgp impairs doxorubicin-mediated ICD and if Pgp
inhibitors, originally designed as chemosensitizing agents, may be considered as ICD-inducers
in combination with doxorubicin. To this aim, we compared Tariquidar and compound R-3—the
first-in-class compound of a library of N,N-bis(alkanol)amine aryl ester derivatives recently synthesized
by our group [23]—that has an EC50 for Pgp activity (73 nM) comparable to Tariquidar (74 nM) [24].
We demonstrated that the reduction of Pgp on cell surface but not the simple inhibition of the transporter
activity is required to restore doxorubicin-mediated ICD.
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2. Materials and Methods
2.1. Chemicals
Fetal bovine serum (FBS) and culture medium were acquired from Invitrogen Life Technologies
(Carlsbad, CA, USA). Plasticware for cell cultures was from Falcon (Becton Dickinson, Franklin Lakes,
NJ, USA). The protein content in cell extracts was assessed with the BCA kit from Sigma-Merck (St.
Louis, MO, USA). Electrophoresis reagents were obtained from Bio-Rad Laboratories (Hercules, CA).
Doxorubicin and Tariquidar were purchased by Sigma-Merck. R-3 synthesis and characterization is
reported in [23]. The structures of Tariquidar and R-3 are shown in Supplementary Figure S1.
2.2. Cells
Human doxorubicin-sensitive colon cancer HT29 cells, non-small cell lung cancer A549 cells,
and triple-negative breast cancer MDA-MB-231 cells were purchased from ATCC (Manassas, VA,
USA). The corresponding doxorubicin-resistant variants (HT29/DX, A549/DX, and MDA-MB-231 DX)
were selected by culturing parental cells in medium containing progressively increasing doxorubicin
dosages [25], and maintained at a final doxorubicin concentration of 200 nM (HT29/DX), 100 nM
(A549/DX), and 200 nM (MDA-MB-231/DX). Culture medium was supplemented with 10% v/v FBS, 1%
v/v penicillin–streptomycin, and 1% v/v l-glutamine. All cell lines were authenticated by microsatellite
analysis, using the PowerPlex kit (Promega Corporation, Madison, WI, USA; last authentication:
November 2019).
2.3. Immunoblotting
Cells were lysed in MLB buffer (125 mM Tris-HCl, 750 mM NaCl, 1% v/v NP40, 10% v/v glycerol,
50 mM MgCl2, 5 mM EDTA, 25 mM NaF, 1 mM NaVO4, 10 mg/mL leupeptin, 10 mg/mL pepstatin,
10 mg/mL aprotinin, 1 mM phenylmethylsulphonyl fluoride PMSF, pH 7.5), sonicated and centrifuged
at 13,000× g for 10 min at 4 ◦C. Fifty micrograms of proteins was subjected to immunoblotting
and probed with the following antibodies: anti-ABCB1/Pgp (C219, Novus Biologicals, Littleton,
CO, USA; dilution 1/250), anti-ABCC1/MRP1 (IU2H10, Abcam, Cambridge, UK; dilution 1/100),
anti-ABCG2/BCRP (sc-25882, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA; dilution 1/500),
followed by a peroxidase-conjugated secondary antibody. Proteins were detected by enhanced
chemiluminescence (Bio-Rad Laboratories). Plasma membrane-associated proteins were evaluated
in biotinylation assays, using the Cell Surface Protein Isolation kit (Thermo Fisher Scientific Inc.,
Rockford, IL, USA) [15], and probed with anti-Pgp and anti-CRT (PA3-900, ABR-Affinity BioReagents
Inc., Golden, CO, USA; dilution 1/500) antibodies. Non-biotinylated proteins, i.e., cytosolic proteins,
were blotted with the anti-Pgp antibody. Anti-β-tubulin antibody (sc-5274, Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA; dilution 1/1000) was used as control of equal protein loading in cytosolic
extracts; anti-pancadherin antibody (CH-19; Santa Cruz Biotechnology Inc., dilution 1/500) was
used as control in plasma membrane extracts. In co-immunoprecipitation experiments, 100 µg
of plasma membrane-associated proteins were immunoprecipitated with the anti-CRT antibody,
using PureProteome protein A and protein G Magnetic Beads (Millipore, Bedford, MA, USA), and then
blotted for Pgp. To assess Pgp ubiquitination, 50 µg whole cell lysate was immunoprecipitated with
the anti-Pgp antibody, and then probed with an anti-mono/polyubiquitin antibody (FK2, Axxora,
Lausanne, Switzerland; dilution 1/1000).
2.4. Intracellular Doxorubicin Accumulation and Doxorubicin Kinetic Efflux
The intracellular doxorubicin content and the drug efflux were measured as detailed in [26].
The intracellular doxorubicin concentration was expressed as nanomoles doxorubicin/mg cellular
proteins. The efflux of doxorubicin was expressed as the change in the intracellular concentration of
the drug/minute (dc/dt) [26]. Km and Vmax parameters were estimated using the Enzfitter software
(Biosoft Corporation, Cambridge, UK).
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2.5. ATPases Activity
Pgp, MRP1, and BCRP were immunoprecipitated from 100 µg of membrane-associated proteins,
then the rate of ATP hydrolysis, an index of the catalytic cycle and a necessary step for substrate efflux,
was measured spectrophotometrically [27]. In each set of experiments, 0.5 mM Na3VO4 was included
in the reaction mix to measure the Na3VO4-sensitive rate of ATP hydrolysis. Results were expressed as
nmoles hydrolyzed phosphate/mg protein.
2.6. Caspase 3 Activity
Cells were lysed in 0.5 mL of lysis buffer (20 mM Hepes/KOH, 10 mM KCl, 1.5 mM MgCl2,
1 mM EGTA, 1 mM EDTA, 1 mM dithiotreitol DTT, 1 mM PMSF, 10 µg/mL leupeptin, pH 7.5).
Twenty micrograms of cell lysates was incubated for 1 h at 37 ◦C with 20 µM of the fluorogenic
substrate of caspase-3 Ac-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin (DEVD-AMC), in 0.25 mL of
assay buffer (25 mM Hepes, 0.1% w/v 3-((3-cholamidopropyl)-dimethylammonio)-1-propanesulfonate
CHAPS, 10% w/v sucrose, and 10 mM DTT, 0.01% w/v egg albumin, pH 7.5). The reaction was
stopped by adding 0.75 mL of ice-cold 0.1% w/v trichloroacetic acid, and the fluorescence of AMC
fragment released by active caspases was read using a Synergy HT Multi-Detection Microplate Reader
(Bio-Tek Instruments, Winooski, VT, USA). Excitation and emission wavelengths were 380 and 460 nm,
respectively. Fluorescence was converted in nmoles AMC/mg cellular proteins, using a calibration
curve prepared previously with standard solutions of AMC.
2.7. Cell Viability
Cell viability was evaluated using the ATPLite kit (PerkinElmer, Waltham, MA, USA). The results
were expressed as percentage of viable cells in each experimental condition versus untreated cells
(considered 100% viable).
2.8. Proximity Ligation Assay
The CRT–Pgp interaction was measured with the DuoLink In Situ Kit (Sigma-Merck), as per
manufacturer’s instructions, using the mouse anti-Pgp (UIC-2, Millipore; dilution 1/50) and the
rabbit anti-CRT (PA3-900, ABR-Affinity BioReagents Inc.; dilution 1/50) antibodies. Cell nuclei were
counterstained with 4′,6-diamidino-2-phenylindole (DAPI). Cells were examined using a Leica DC100
fluorescence microscope (Leica Microsystem, Wetzlar, Germany).
2.9. Confocal Microscope Analysis
Cells were seeded onto glass coverslips, and transduced with the CellLight Early Endosomes-GFP
Reagent BacMam 2.0 (Invitrogen, Milan, Italy), containing an expression vector for green fluorescent
protein (GFP)-Rab5a, according to the manufacturer’s instructions. Cells were then fixed using 4%
v/v paraformaldehyde for 15 min, washed with PBS, and incubated for 1 h at room temperature with
a red phycoerythrin (PE)-conjugated anti-Pgp (UIC-2, Millipore; dilution 1/100) antibody, washed
with PBS and deionized water. Cells were examined using a Leica TCS SP2 AOP confocal laser
scanning microscope.
2.10. Surface CRT Expression, ATP and HMGB1 Release
To measure the levels of surface CRT, 1 × 105 cells were washed with PBS, detached with Cell
Dissociation Solution (Sigma-Merck), and incubated for 45 min at 4 ◦C with the anti-CRT antibody
(Affinity Bioreagents; dilution 1/100), followed by an AlexaFluor488-conjugated secondary antibody
(Abcam; dilution 1/50) for 30 min at 4 ◦C. After the fixation step in 2.5% v/v paraformaldehyde
for 5 min at room temperature, samples were analyzed with a Guava EasyCyte (Millipore) flow
cytometer equipped with the InCyte software (Millipore). Propidium iodide-negative, CRT-positive
cells were counted. Cells incubated with an isotype control antibody, followed by secondary antibody,
Cells 2020, 9, 1033 5 of 17
were included as control of specificity. The ATP release was measured on 100 µL of the cell culture
medium with the ATP Bioluminescent Assay Kit (FL-AA, Sigma-Merck). The results were expressed
as nmoles/mg cellular proteins. The release of HMGB1 was measured using the High Mobility Group
Protein 1 ELISA kit (Cloud-Clone Corp., Houston, TX, USA), as per manufacturer’s instructions.
The results were expressed in nmoles/mg cellular proteins.
2.11. Phagocytosis and T Lymphocyte Activation
DCs were generated from monocytes, immuno-magnetically isolated from peripheral blood of
healthy donors, provided by Blood Bank of AOU Città della Salute e della Scienza, Torino, Italy,
as previously reported [28]. The Ethical Approval by Institutional Review Board (Comitato Etico
Interaziendale A.O.U. Citta‘ della Salute e della Scienza di Torino—A.O. Ordine Mauriziano—A.S.L.
TO1) is: DG 767/2015. The phagocytosis assay was performed as detailed in [6], by co-incubating DCs
and tumor cells at 37 ◦C and 4 ◦C for 24 h. The percentage of phagocytized cells obtained after the
incubation at 4 ◦C was subtracted from the percentage obtained at 37 ◦C, and was always less than 5%
(not shown). The phagocytosis rate was expressed as phagocytic index [6]. After cell phagocytosis,
DCs were washed and co-cultured for 10 days with autologous T-cells, isolated by immuno-magnetic
sorting with the Pan T Cell Isolation Kit (Miltenyi Biotec., Tetrow, Germany). The expression of CD107,
a degranulation marker and an index of active CD8+CTLs, was determined by flow cytometry [16],
using anti-human fluorescein isothyocyanate (FITC)-conjugated-CD8 (clones BW135/80 and 53–6.7;
dilution 1/10) and PE-conjugated-CD107 (clones H4A3 and 1D4B; dilution 1/10) antibodies (Miltenyi
Biotec.). The production of IFN-γ in the culture supernatant of CD8+T-cells co-cultured with DCs—a
second parameter of CD8+T-cells cytotoxic activity [28]—was measured with the Human IFN-γ DuoSet
Development Kit (R&D Systems, Minneapolis, MN, USA). Results were expressed as ng/mL.
2.12. Generation of Pgp-Knocked out (KO) Clones
5 × 105 cells were transduced with 1 µg CRISPR pCas vectors (#KN414470, Origene, Rockville,
MD, USA) targeting Pgp, respectively, or with 1 µg non-targeting vector (Origene), following the
manufacturer’s instructions. Stable KO cells were selected from medium containing 1µg/mL puromycin
for 4 weeks.
2.13. Statistical Analysis
All data in the text and figures are provided as mean ± SD. The results were analyzed by one-way
ANOVA test (without corrections for multiple assessments) using Statistical Package for Social Science
(SPSS) software (IBM SPSS Statistics v.19).
3. Results
3.1. R-3 Increases Doxorubicin Intracellular Content and Cytotoxicity by Inhibiting Pgp Activity
We first analyzed the potential of R-3 in reversing doxorubicin resistance in human cancer cell lines
of different origin (i.e., colon, lung, and breast cancer), characterized by sensitivity or acquired resistance
to the drug [29]. Compared to the sensitive counterparts, HT29/DX and A549/DX cells had higher levels
of Pgp and MRP1, and MDA-MB-231/DX cells had increased levels of Pgp (Figure 1A). Neither R-3
nor Tariquidar, used at a concentration comparable to their EC50 [23,24], increased doxorubicin
intracellular content within Pgp-lowly expressing HT29, A549, and MDA-MB-231 cells, but they did so
in Pgp-expressing variants (Figure 1B). Like Tariquidar, R-3 specifically reduced the catalytic activity
of Pgp (Figure 1C), but it did not change the ATPase rate of other ABC transporters involved in
doxorubicin efflux, such as MRP1 and BCRP (Supplementary Figure S2). Notably, in MDA-MB-231/DX
cells, R-3 increased doxorubicin’s Km and decreased Vmax of doxorubicin efflux, whereas Tariquidar
only increased Km (Figure 1D; Table 1). This trend suggests that R-3 reduced the affinity of doxorubicin
for Pgp and likely decreased the amount of active Pgp.
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Figure 1. R-3 increases doxorubicin intracellular content by inhibiting Pgp activity. (a) Immunoblotting
of the indicated proteins in human colon cancer HT29 cells, non-small cell lung cancer A549 cells,
triple-negative breast cancer MDA-MB-231 cells, and in their doxorubicin (DX)-resistant variants.
Tubulin was used as control of equal protein loading. The image is representative of 1 out of 3
experiments. (b) Cells were incubated for 3 h in medium containing 5 µM doxorubicin (dox), in the
absence (ctrl) or presence of 75 nM Tariquidar (Tar) or 75 nM R-3. Intracellular doxorubicin content
was measured fluorimetrically in duplicates (n = 3). Data are means ± SD. * p < 0.005: treated cells
vs. respective ctrl cells; ◦ p < 0.001: DX cells vs. parental cells. (c) Cells were grown for 24 h in the
absence (ctrl) or presence of 75 nM Tariquidar (Tar) or 75 nM R-3. Pgp ATPase activity was measured
spectrophotometrically on membrane extracts of DX variants. Data are means ± SD (n = 3). * p < 0.001:
treated cells vs. respective ctrl cells. (d) MDA-MB-231/DX cells were grown in the absence (ctrl) or
presence of 75 nM Tariquidar (Tar) or 75 nM R-3 for 24 h, then incubated for 20 min with increasing
concentrations (0–50 µM) of doxorubicin (dox). The procedure was repeated on a second series of
dishes, incubated in the same experimental conditions and analyzed after 10 min. Data are means ±
SD (n = 3). The rate of doxorubicin efflux (dc/dt) was plotted versus the intracellular concentration of
the drug.
Table 1. Kinetic parameters of doxorubicin efflux in MDA-MB-231/DX cells.
Experimental Condition Km Vmax
ctrl 0.19 ± 0.04 4.41 ± 0.56
+ Tar 0.94 ± 0.15 * 3.82 ± 0.83
+ R-3 0.76 ± 0.19 * 1.32 ± 0.42 *,1
1 MDA-MB-231/DX cells were grown in the absence (ctrl) or presence of 75 nM Tariquidar (Tar) or 75 nM R-3 for 24
h, and then treated as reported in Figure 1D. Km (µM) and Vmax (µmole /min) were calcul ted with the Enzfitter
software. * p < 0.001: treated cells vs. respective ctrl cells.
As expected, doxorubicin increased the rate of apoptosis, indicated by the activity of caspase 3
(Figure 2A), and re uced the viability (Figure 2B) in sensitive HT29, A549, and MDA-MB-231 cells,
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but it was ineffective in the resistant variants. R-3 increased the rate of apoptosis and decreased the cell
viability upon doxorubicin treatment, as did Tariquidar (Figure 2A,B).
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Figure 2. R-3 increases doxorubicin-induced apoptosis and cytotoxicity in Pgp-expressing cells.
(a) Human colon cancer HT29 cells, non-small cell lung cancer A549 cells, triple-negative breast
cancer MDA-MB-231 cells, and their doxorubicin (DX)-resistant variants were incubated 24 h (a) or
48 h (b), in fresh medium (ctrl), without inhibitors (- in) or with 75 nM Tariquidar (Tar) or 75 nM
R-3. When indicated, 5 µM doxorubicin (dox) was added. (a) Activity of caspase 3 was measured
fluorimetrically in duplicates (n = 3). Data are means± SD. * p < 0.001: treated cells vs. respective ctrl cells;
◦ p < 0.001: DX cells vs. parental cells. (b) Cell viability was measured by a chemiluminescence-based
assay in quadruplicates. Data are means ± SD (n = 3). * p < 0.001: treated cells vs. respective ctrl cells; ◦
p < 0.05: DX cells vs. parental cells.
To investigate if R-3 and Tariquidar were also able to rescue the doxorubicin-induced ICD, we next
focused on MDA-MB-231 cells and their resistant counterpart, where Pgp was the main transporter
involved in doxorubicin efflux.
3.2. R-3 but Not Tariquidar Restores Doxorubicin-Induced Immunogenic Death in Resistant Cell Lines
Doxorubicin, alone or combined with R-3 and Tariquidar, increased the pre-apoptotic translocation
of CRT on cell surface (Figure 3A) and the release of ATP (Figure 3B) and HMGB1 (Figure 3C) in
sensitive MDA-MB-231 cells. In keeping with this result, doxorubicin-treated cells were more
phagocytized (Figure 3D; Supplementary Figure S3); after phagocytosis, DCs induced the expansion
of activated CTLs, i.e., CD8+CD107a+T-cells (Figure 3E) releasing IFN-γ (Figure 3F). Likely as a
consequence of the lower intracellular accumulation (Figure 1B), doxorubicin did not elicit any
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immunogenic effect in the MDA-MB-231/DX variant. Unexpectedly, although Tariquidar and R-3
increased intracellular accumulation of doxorubicin (Figure 1B), CRT translocation (Figure 3A), and ATP
(Figure 3B) and HMGB1 (Figure 3C) release occurred to a similar extent in resistant cells, and only
R-3, but not Tariquidar, increased the cell phagocytosis (Figure 3D) and the percentage of activated
CD8+T-lymphocytes (Figure 3E,F) to the same level of sensitive MDA-MB-231 cells.
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Figure 3. R-3 but not Tariquidar rescues the i munogenic cell death induced by doxorubicin in
Pgp-expressing cells. (a) Human triple-negative breast cancer MDA-MB-231 cells and their doxorubicin
(DX)-resistant vari nt were incubated 6 h (a and b) or ), in fresh medium (ctrl) or in medium
contai ing 5 µM dox rubicin (dox). Cells were gro t inhibitors (- in), with 75 nM Tariquidar
(Tar) o 75 nM R-3. (a) Dot plots representative f calreticulin (CRT), performed by flow
cytometry in duplicate (n = 3). Numbers repres t t tage of cells/quadrant. Cut-off for
positivity was fixed at 102. SS : side-scatter. The image is representative of 1 out of 3 experiments.
(b) Release of extracellular ATP, measured by a chemiluminescence-based assay in duplicates (n =
3). Data are means ± SD. * p < 0.001: treated cells vs. respective ctrl cells; ◦ p < 0.001: DX cells vs.
parental cells. (c) Release of extracellular HMGB1, measured by ELISA in duplicates (n = 3). Data are
means ± SD. * p < 0.001: treated cells vs. respective ctrl cells; ◦ p < 0.001: DX cells vs. parental cells.
(d) After the treatments indicated in panel (c), tumor cells were stained with FITC-PKH2 dye and DCs
were stained with an anti-PE-HLA-DR antibody. Tumor cells were co-incubated with DCs for 24 h.
Double-stained cells were counted by flow cytometry. Data are means ± SD (n = 3). * p < 0.001: treated
cells vs. respective ctrl cells; ◦ p < 0.001: DX cells vs. parental cells. (e) T-lymphocytes were co-cultured
with DCs after phagocytosis, and then incubated 24 h with MDA-MB-231 or MDA-MB-231/DX cells.
The percentage of CD8+CD107a+T-cells was measured by flow cytometry. Data are means ± SD (n =
3). * p < 0.001: treated cells vs. respective ctrl cells; ◦ p < 0.001: DX cells vs. parental cells. (f) IFN-γ
concentration was measured in the supernata ts of T-lymphocytes, treated as indicated in (e), by ELISA
in duplicates. Data are means ± SD (n = 3). * p < 0.001: treated cells vs. respective ctrl cells; ◦ p < 0.001:
DX cells vs. parental cells.
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3.3. Pgp Internalization and Degradation Restores Immunogenic Cell Death
Tariquidar is a competitive inhibitor of Pgp [30], while R-3 is not [23], although they both reduced
the efflux of doxorubicin through Pgp. To clarify why these two inhibitors of Pgp produced such
different effects on ICD, we wondered whether they affected the amount of surface Pgp that we
previously identified as an inhibitor of CRT immunogenic functions [19].
We first investigated the interaction between Pgp and CRT on plasma membrane, using a
proximity ligation approach. As expected, untreated cells or cells treated with Tariquidar or R-3
alone, where CRT translocation was absent, did not produce any signal of Pgp-CRT interaction
(Figure 4A). Doxorubicin-treated MDA-MB-231 cells, which had constitutively amounts of Pgp
(Figure 1A) and induced the translocation of CRT (Figure 3A), showed Pgp-CRT proximity, in contrast
with doxorubicin-treated MDA-MB-231/DX cells that had high levels of Pgp (Figure 1A) but did not
expose CRT (Figure 3A). Both doxorubicin-sensitive and doxorubicin-resistant sublines treated with
Tariquidar and doxorubicin showed an interaction between Pgp and CRT (Figure 4A), suggesting
that in this condition the two proteins where associated on cell surface. The presence of Pgp and its
interaction with CRT may explain why Tariquidar did not induce phagocytosis in MDA-MB-231/DX cells
(Figure 3D), although it increased doxorubicin content (Figure 1B) and CRT translocation (Figure 3A).
By contrast, MDA-MB-231/DX cells treated with R-3 and doxorubicin did not display any signal of
interaction (Figure 4A), notwithstanding the translocation of CRT (Figure 3A). Notably, the combination
of R-3 and doxorubicin restored ICD in these resistant cells (Figure 3).Cells 2020, 9, x 10 of 17 
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variant were incubated for 24 h in fresh medium (ctrl) or in medium containing 5 µM doxorubicin
(dox). When indicated, 75 nM Tariquidar (Tar) or 75 nM R-3 were added. (a) Proximity ligation
assay between Pgp and calreticulin. Blank: cells incubated without primary antibodies. Blue signal:
nuclear staining (DAPI). Green signal: Pgp/calreticulin interaction. The image is representative of 1
out of 3 experiments. A minimum of 5 fields/experiment was examined. Bar: 10 µm (10× ocular lens;
63× objective lens). (b) Plas a membrane extracts were immunoblotted and decorated to detect Pgp
or CRT, or immuno-precipitated (IP) with an anti-CRT antibody, then immun blotted (IB) with an
anti-Pgp antibody. no Ab: MDA-MB-231 and MDA-MB-231/DX samples treated with doxorubicin,
immuno-precipitated without antibodies. An aliquot of the extract before th immunoprecipitation
was probed with an anti-pancadherin antibody, as c ntrol of equal protein loading. The figure is
representative of 1 out of 3 ex eriments. (c) MDA-MB-231/DX cells were incubated 24 h with 75 nM R-3.
During the l st 18 h, cells were transfect d with an expression vector for GFP-conj g Rab5a, to label
early endosomes. Subsequently, cells were labeled with an anti-PE-Pgp antibody. Immunofluorescence
detection of Pgp co-localized with Rab5a was achieved by confocal microscope analysis. The image
is representative of 1 out of 3 experiments. A minimum of 5 fields/experiment was examined. Bar:
10 µm (10× ocular lens; 60× objective lens). (d) Whole cell extracts of MDA-MB-231/DX cells were
immunoprecipitated with an anti-Pgp antibody, then immunoblotted for ubiquitin (UQ). An aliquot
of the extracts before the immunoprecipitation was probed with an anti-Pgp antibody, as index of
the total amount of Pgp immunoprecipitated in each sample. The figure is representative of 1 out of
3 experiments.
We next measured the amount of Pgp and CRT on plasma membrane extracts by a biotinylation
assay. MDA-MB-231 cells showed low levels of Pgp that were not affected by doxorubicin or Tariquidar;
the same was true in MDA-MB-231/DX cells, although the amount of Pgp on the cell surface was
higher. Interestingly, Pgp on plasma membrane was drastically reduced by R-3 (Figure 4B). As far as
CRT is concerned, the results of biotinylation assay were in line with the flow cytometry measures
(Figure 3A): doxorubicin increased surface CRT in MDA-MB-231 cells, not in the resistant variant.
In both sensitive and resistant cells, the associations of doxorubicin plus Tariquidar, or doxorubicin
plus R-3, induced the translocation of CRT to the plasma membrane. Consistently with the relative
amounts of Pgp and CRT, co-immunoprecipitation assays on plasma membrane extracts revealed a
weak association between Pgp and CRT in MDA-MB-231 cells upon treatment with doxorubicin or
Tariquidar plus doxorubicin, and a strong association in MDA-MB-231/DX cells treated with Tariquidar
plus doxorubicin. Notably, R-3-treated cells did not display any co-immunoprecipitation of Pgp and
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CRT, likely as a consequence of the reduced amount of Pgp on plasma membrane (Figure 4B). Such
decrease was not due to a reduced amount of Pgp in cytosolic extracts (Supplementary Figure S4).
Next, we investigated if the decrease in Pgp from the plasma membrane elicited by R-3 was due
to its internalization. The co-labeling of MDA-MB-231/DX cells for Pgp and Rab5a, an early endosome
marker, indicated that in R-3-treated cells Pgp was internalized within the endosomal compartment
(Figure 4C). Moreover, R-3 induced a strong ubiquitination of Pgp, not elicited by doxorubicin nor
Tariquidar (Figure 4D). This experimental set indicates that R-3, differently from Tariquidar, is a good
inducer of ICD not only because it increased the doxorubicin content, but also because it reduced the
amount of Pgp interacting with CRT on cell surface.
3.4. Pgp Removal is Necessary to Restore Immunogenic Cell Death in Doxorubicin-Resistant Cells
As further confirmation that Pgp removal is required to induce ICD in chemoresistant cells,
we knocked out (KO) the protein in MDA-MB-231/DX cells (Figure 5A). Pgp-KO cells increased the
exposure of CRT in response to doxorubicin (Figure 5B), as well as the release of ATP (Figure 5C)
and HMGB1 (Figure 5D). After co-culture with DCs, KO cells treated with doxorubicin were well
phagocytized (Figure 5E) and able to expand CD8+CD107a+CTLs (Figure 5F) producing IFN-γ
(Figure 5G). Overall, in MDA-MB-231/DX cells treated with doxorubicin, Pgp removal restored the
ICD-related parameters (Figure 5) to the same level as doxorubicin-sensitive cells (Figure 3).
Cells 2020, 9, x 11 of 17 
 
R-3. During the last 18 h, cells were transfected with an expression vector for GFP-conjugated Rab5a, 
to label early endosomes. Subsequently, cells were labeled with an anti-PE-Pgp antibody. 
Immunofluorescence detection of Pgp co-localized with Rab5a was achieved by confocal microscope 
analysis. The image is representative of 1 out of 3 experiments. A minimum of 5 fields/experiment 
was examined. Bar: 10 μm (10× ocular lens; 60× objective lens). (d) Whole cell extracts of MDA-MB-
231/DX cells were immunoprecipitated with an anti-Pgp antibody, then immunoblotted for ubiquitin 
(UQ). An aliquot of t e tracts before the immunoprecipitation was probed with an anti-Pgp 
antibody, as index of the total amount of Pgp immunoprecipitated in each ample. The figure is 
representative of 1 out of 3 experiments. 
3.4. Pgp e oval is ecessary to estore I unogenic ell eath in oxorubicin- esistant ells 
s further confirmation that Pgp removal is required to induce ICD in chemoresistant cells, we 
knocked out (KO) the protein in MDA-MB-231/DX cells (Figure 5A). Pgp-KO cells increased the 
ex os re of CRT in response to doxorubicin (Figure 5B), as well as the release of ATP (Figure 5C) and 
HMGB1 (Figure 5D). After co-culture with DCs, KO cells treated with doxorubicin ere ell 
agocytize  (Figure 5E) and able to expand CD8+CD107a+CTLs (Figure 5F) producing IFN-γ (Figure 
5G). Overall, in MDA-MB-231/DX cells treated with doxorubicin, Pgp removal restored the ICD-
related parameters (Figure 5) to the same level as doxorubicin-sensitive cells (Figure 3). 
 
Figure 5. Pgp knock-out restores doxorubicin-induced immunogenic cell death. MDA-MB-231/DX 
cells (wild type, wt) were transduced with a non-targeting vector (scrambled vector; scr) or with two 
CRISPR pCas Pgp-targeting vectors (KO#1, KO#2). Cells were grown in fresh medium (- dox) or in 
the presence of 5 μM doxorubicin (+ dox), for 6 h (b and c) or 24 h (d–f). (a) Pgp immunoblotting in 
whole cell extracts. Tubulin was used as control of equal protein loading. The image is representative 
of 1 out of 3 experiments. (b) Dot plots representative of surface calreticulin (CRT), performed by flow 
cytometry in duplicates (n = 3). Numbers represent the percentage of cells/quadrants. Cut-off for 
positivity was fixed at 102. SSC: side-scatter. The image is representative of 1 out of 3 experiments. (c) 
Cells 2020, 9, x 11 of 17 
 
R-3. During the last 18 h, cells were transfected with an expression vector for GFP-conjugated Rab5a, 
to label early endosomes. Subsequently, cells were labeled with an anti-PE-Pgp antibody. 
Immunofluorescence detection of Pgp co-localized with Rab5a was achieved by confocal microscope 
analysis. The image is representative of 1 out of 3 experiments. A minimum of 5 fields/experiment 
was examined. Bar: 10 μm (10× ocular lens; 60× objective lens). (d) Whole cell extracts of MDA-MB-
231/DX cells were immunoprecipitated with an anti-Pgp antibody, then immunoblotted for ubiquitin 
(UQ). An aliquot of the extracts before the immunoprecipitation was probed with an anti-Pgp 
antibody, as index of the total amount of Pgp immunoprecipitated in each sample. The figure is 
representative of 1 out of 3 experiments. 
3.4. Pgp Removal is Necessary to Restore Immunogenic Cell Death in Doxorubicin-Resistant Cells 
As further confirmation that Pgp removal is required to induce ICD in chemoresistant cells, we 
knocked out (KO) the protein in MDA-MB-231/DX cells (Figure 5A). Pgp-KO cells increased the 
exposure of CRT in response to doxorubicin (Figure 5B), as well as the release of ATP (Figure 5C) and 
HMGB1 (Figure 5D). After co-culture with DCs, KO cells treated with doxorubicin were well 
phagocytized (Figure 5E) and able to expand CD8+CD107a+CTLs (Figure 5F) producing IFN-γ (Figure 
5G). Overall, in MDA-MB-231/DX cells treated with doxorubicin, Pgp removal restored the ICD-
related parameters (Figure 5) to the same level as doxorubicin-sensitive cells (Figure 3). 
 
Figure 5. Pgp knock-out restores doxorubicin-induced immunogenic cell death. MDA-MB-231/DX 
cells (wild type, wt) were transduced with a non-targeting vector (scrambled vector; scr) or with two 
CRISPR pCas Pgp-targeting vectors (KO#1, KO#2). Cells were grown in fresh medium (- dox) or in 
the presence of 5 μM doxorubicin (+ dox), for 6 h (b and c) or 24 h (d–f). (a) Pgp immunoblotting in 
whole cell extracts. Tubulin was used as control of equal protein loading. The image is representative 
of 1 out of 3 experiments. (b) Dot plots representative of surface calreticulin (CRT), performed by flow 
cytometry in duplicates (n = 3). Numbers represent the percentage of cells/quadrants. Cut-off for 
positivity was fixed at 102. SSC: side-scatter. The image is representative of 1 out of 3 experiments. (c) 
Cells 2020, 9, 1033 12 of 17
Figure 5. Pgp knock-out restores doxorubicin-induced immunogenic cell death. MDA-MB-231/DX
cells (wild type, wt) were transduced with a non-targeting vector (scrambled vector; scr) or with two
CRISPR pCas Pgp-targeting vectors (KO#1, KO#2). Cells were grown in fresh medium (- dox) or in
the presence of 5 µM doxorubicin (+ dox), for 6 h (b and c) or 24 h (d–f). (a) Pgp immunoblotting in
whole cell extracts. Tubulin was used as control of equal protein loading. The image is representative
of 1 out of 3 experiments. (b) Dot plots representative of surface calreticulin (CRT), performed by
flow cytometry in duplicates (n = 3). Numbers represent the percentage of cells/quadrants. Cut-off for
positivity was fixed at 102. SSC: side-scatter. The image is representative of 1 out of 3 experiments.
(c) Release of extracellular ATP, measured by a chemiluminescence-based assay in duplicates (n =
3). Data are means ± SD. * p < 0.001: KO-cells vs. scr-cells; ◦ p < 0.001: + dox cells vs. - dox cells.
(d) Release of extracellular HMGB1, measured by ELISA in duplicates (n = 3). Data are means ± SD. *
p < 0.001: KO-cells vs. scr-cells; ◦ p < 0.001: + dox cells vs. - dox cells. (e) After the treatment indicated
in panel (d), tumor cells were stained with FITC-PKH2 dye, DCs were stained with an anti-PE-HLA-DR
antibody. Tumor cells were co-incubated with DCs for 24 h. Double-stained cells were counted by flow
cytometry. Data are means ± SD (n = 3). * p < 0.001: KO-cells vs. scr-cells; ◦ p < 0.001: + dox cells
vs. - dox cells. (f) T-lymphocytes were co-cultured with DCs after phagocytosis, and then incubated
24 h with scr- or KO-cells. The percentage of CD8+CD107a+T-cells was measured by flow cytometry.
Data are means ± SD (n = 3). * p < 0.001: KO-cells vs. scr-cells; ◦ p < 0.001: + dox cells vs. - dox cells.
(g) IFN-γ concentration was measured in the supernatants of T-lymphocytes, treated as indicated in
panel (f), by ELISA in duplicates. Data are means ± SD (n = 3). * p < 0.001: KO-cells vs. scr-cells; ◦
p < 0.001: + dox cells vs. - dox cells.
4. Discussion
In this work, we investigated the role of Pgp in inducing resistance to ICD in cancer cells and we
evaluated which types of Pgp inhibitors can be ICD-restoring agents.
To this aim, we screened different cell lines with acquired resistance to doxorubicin, consequent to
a stepwise selection with the drug [25]. This strategy mimics in vitro the progressive exposure to a
cumulative dosage of chemotherapy that may lead to the acquisition of chemoresistance in patients.
The cell lines generated all had higher Pgp levels, decreased accumulation of doxorubicin, reduced
apoptosis, and higher cell viability if treated with doxorubicin, independently from the tumor type.
We previously observed that Pgp-expressing variants are resistant to ICD when treated with doxorubicin,
at a dosage that elicits ICD in parental doxorubicin-sensitive counterparts [15,16]. This resistance to
doxorubicin-induced ICD was observed also in MDA-MB-231/DX cells, i.e., the doxorubicin-resistant
variant with the highest levels of Pgp and the lowest retention of doxorubicin, among the cell lines tested.
Indeed, MDA-MB-231/DX cells did not translocate CRT, nor release ATP and HMGB1. In keeping
with these findings, they were not phagocytized by DCs and were not able to expand activated (i.e.,
CD107a+, IFN-γ-producing) CTLs.
One reason for this ICD resistance could be the active efflux of doxorubicin by Pgp that limits the
drug’s intracellular retention. The low amount of the drug inside the cells became insufficient to elicit
ER stress [31], a key event in doxorubicin-induced ICD [2,6,7]. We thus evaluated if pharmacological
inhibitors of Pgp may restore doxorubicin-induced ICD in Pgp-expressing cells.
We compared Tariquidar, the latest clinically tested Pgp inhibitor [22], and R-3, a N,N-bis(alkanol)
amine aryl ester derivative recently synthesized by our group, with an EC50 for Pgp similar to
Tariquidar [23,24]. Tariquidar is reported to bind to the drug binding pocket of the protein, in particular,
to the so-called H-site, which is localized within the inner leaflet of the membrane at 10.5 to 14.5 Ǻ
apart from the membrane surface [32], and it was suggested that it inhibits Pgp pumping from the
cytoplasmic face of the membrane [33]. This compound has shown a great ability to potentiate the
toxicity of doxorubicin in different cancer cells overexpressing Pgp [34,35]. R-3 belongs to a library
of compounds that bind to the hydrophobic pocket and with transmembrane helixes of Pgp: these
interactions likely alter the Pgp functions [23]. Both Tariquidar and R-3 indeed decreased Pgp ATPase
activity and increased doxorubicin retention and toxicity. Next, we analyzed in details the effects
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of R-3 on doxorubicin efflux kinetics: we found that Tariquidar increased Km but did not change
Vmax, whereas R-3 produced higher Km and lower Vmax. The altered Km indicates a lower affinity of
doxorubicin for Pgp, suggesting that the compounds interfere with the doxorubicin binding to the
transporter. The lower Vmax is instead indicative of a lower amount of active Pgp present on the cell
surface [26]. Notably, both inhibitors induced the exposure of CRT on cell surface of MDA-MB-231/DX
cells treated with doxorubicin, as well as the release of ATP and HMGB1. These two actions suggested
that they both release the tumor-dependent signals necessary to trigger ICD. Unexpectedly, however,
Tariquidar-treated cells were not phagocytized by DCs nor were able to activate CD8+CTLs, while
R-3-treated cells underwent a complete ICD process.
Besides the endogenous signals of cancer cells, ICD is complete when DCs are attracted within
the tumor bed, primed to phagocytize, and mature. ATP is a soluble inducer of all these processes [36].
Furthermore, DCs are fully engaged by direct ligand–receptor contacts with tumor cells, such as the
contacts between CRT/ERp57 and LDL receptor-related protein1/CD91 [6,7] or between HSP90 and
TLR4 [11]. Pgp inhibits the CRT-mediated phagocytosis of cancer cells, likely by a direct interaction
with CRT in colon cancer HT29/DX cells [19]. The proximity ligation and co-immunoprecipitation
assays of surface proteins confirmed a physical interaction between Pgp and CRT in sensitive
MDA-MB-231 cells treated with doxorubicin, alone or with Tariquidar, i.e., two conditions associated
with increased intracellular doxorubicin and increased surface CRT. As expected, such interaction
was not detectable in resistant MDA-MB-231/DX cells treated with doxorubicin that was poorly
accumulated within cells. CRT–Pgp interaction was detected in cells exposed to doxorubicin plus
Tariquidar, characterized by an increased doxorubicin content and CRT translocation. By contrast, both
sensitive and resistant cells treated with R-3 had no signals of interaction between Pgp and CRT, despite
a translocation of CRT comparable to Tariquidar-treated cells. The lack of signal in proximity ligation
and co-immunoprecipitation assays was due to the strong reduction of Pgp on the cell surface, elicited
by R-3. This data explains the lower Vmax observed in doxorubicin efflux. Moreover, it explains why
R-3-treated cells—with a reduced amount of Pgp on their surface—were well phagocytized by DCs.
CRT has distinct domains important for its correct folding and immunogenic functions: the highly
conserved amino-terminal domain and the close P domain constitute most of the extracellular portion
of CRT interacting with other proteins [37]. On the other hand, Pgp is an integral membrane protein,
characterized by 12 transmembrane helixes, connected by multiple extracellular loops and two large
intracellular nucleotide binding domains [21]. The shift from an inward open conformation to an
outward open conformation upon drug binding and efflux [21] makes Pgp a highly dynamic protein,
able to transiently interact with other ecto-enzymes. Such interactions can modulate Pgp activity, as in
the case of Pgp-carbonic anhydrase XII interaction [25], or modulate the function of the client protein.
This is the case in the interaction between CRT and Pgp [19], where we hypothesize that Pgp masks
specific CRT domains critical for its immunogenic activity. We are currently producing CRT and Pgp
mutants to clarify the possible sites of interaction between the two proteins.
Lowering the amount of Pgp from cell surface, as in the case of R-3-treated cells, indeed relieved the
inhibition on CRT, allowing the phagocytosis of cancer cells and the subsequent expansion of activated
CD8+CTLs. In particular, R-3 reduced the amount of surface Pgp by inducing its internalization
via endosome and subsequent ubiquitination. Pgp internalization can follow either endosomal or
lysosomal pathways. The endosomal pathway, supported by the observation that Pgp is associated
with the early endosome marker Rab5a [38,39], reduces the amount of Pgp from cell plasma membrane
and results in increased accumulation of Pgp substrates [40]. By contrast, when Pgp is internalized via
lysosomes, it maintains a high activity of Pgp on the lysosome membrane: this type of endocytosis
induces chemoresistance, because it sequesters the chemotherapeutic drugs within lysosomes [41].
The endosome-associated internalization, but not the lysosomal one, results in Pgp ubiquitination [40].
Until now, few agents are described as inducers of Pgp ubiquitination. Among them, there are
sulfhydrating agents such as hydrogen disulfide-releasing doxorubicin [42] or disulfiram [43] that
destabilize disulfide bonds and alter the proper folding of nascent Pgp. Curiously, the tetrandrine
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derivative H1, an inhibitor of Pgp ATPase activity, has been reported to be a strong inducer of Pgp
ubiquitination [44]. We suggest that R-3, interacting with the drug binding pocket and interfering with
the Pgp ATPase cycle, also destabilized the protein and primed it for ubiquitination.
The proof of concept that a high expression of Pgp inhibits ICD was provided by Pgp-KO
MDA-MB-231/DX cells. In these cells, the increase in CRT exposure induced by doxorubicin was
followed by a strong DC-mediated phagocytosis and an increase in CD8+CD107a+/IFN-γ-producing
CTLs. This experimental set indicates that doxorubicin-resistant cells reacquired a complete sensitivity
to ICD, behaving like parental drug-sensitive cells, if Pgp is removed from cell surface.
Triple-negative breast cancer, i.e., the cell model evaluated in the present work, is of particular
interest because it is treated with anthracycline-based chemotherapy. Unfortunately, it is often
chemoresistant because of the high expression of Pgp [43], and therefore characterized by poor
prognosis [45]. On the other hand, breast cancer patients with high CD8+CTL infiltration,
which correlated with a higher intratumor expression of CRT, have a better survival [46]. Increasing the
ICD of triple-negative breast cancer cells with compounds other than conventional chemotherapeutic
drugs [47] has been explored in this resistant cancer type. Our data indicate that specific Pgp
inhibitors may be useful for this purpose. As most of the Pgp inhibitors failed as chemosensitizers
agents [20], their use as ICD-inducers in combination with doxorubicin appears as an interesting
repurposing option.
5. Conclusions
In this work, we demonstrated that doxorubicin-resistant/Pgp-expressing cancer cells are also
resistant to the doxorubicin-induced ICD for at least two reasons: the lower accumulation of doxorubicin
within the cells, due to the active drug efflux via Pgp, and the presence of Pgp itself that impairs
the ability of CRT to recruit DCs and stimulate phagocytosis. Disrupting the CRT-Pgp interaction
using pharmacological Pgp inhibitors may re-sensitize ICD-resistant cells to the immunogenic effect
of chemotherapy. However, inhibitors reducing only the efflux activity of Pgp restore doxorubicin
cytotoxic effects but not ICD. By contrast, inhibitors reducing the activity and amount of Pgp are effective
chemo-immunesensitizing compounds. We suggest that this type of pharmacological inhibitors may
be useful in chemo-immunetherapeutic protocols for resistant tumors.
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Figure S2. MRP1 and BCRP activity in R-3-treated cells. Human colon cancer HT29/DX cells, non-small cell lung cancer 
A549/DX cells, triple negative breast cancer MDA-MB-231/DX cells were cultured in fresh medium (- R-3) or in medium 
containing 75 nM R-3 (+ R-3). MRP1 (a) and BCRP (b) ATPase activity was measured on membrane extracts 
spectrophotometrically in duplicates. Data are means ± SD (n=3).    
 
 
Figure S3. Dot plots representative of phagocytosis of cells by dendritic cells. Human triple negative breast cancer MDA-
MB-231 cells and their doxorubicin (DX)-resistant variant were incubated 24 h in fresh medium (ctrl) or in medium 
containing 5 μM doxorubicin (dox). Cells were grown without inhibitors, with 75 nM Tariquidar (Tar) or 75 nM R-3. Tumor 
cells were stained with FITC-PKH2 dye, DCs were stained with an anti-PE-HLA-DR antibody and co-incubated with DCs for 
24 h. Double-stained cells were counted by flow cytometry performed by flow cytometry in duplicates (n=3). Red circles: 
double-stained population, corresponding to the tumor cells phagocytized. Numbers represent the percentage of 




Figure S4. Amount of Pgp in whole cell extracts. Human triple negative breast cancer MDA-MB-231 cells and their 
doxorubicin (DX)-resistant variant were incubated 24 h, in fresh medium (ctrl) or in medium containing 5 μM doxorubicin 
(dox). When indicated, 75 nM Tariquidar (Tar) or 75 nM R-3 were added. The amount of Pgp was measured in cytosolic 
extracts, excluding the biotinylated plasmamembrane-associated proteins, by immunoblotting. Tubulin was used as control 
of equal protein loading. The image is representative of 1 out of 3 experiments. 
